‘Universal’ Antibody Cocktail Targets Flu Virus Weak Spot

Recent research has demonstrated that a combination of antibodies can provide protection against various strains of the influenza virus in mice. This cocktail of antibodies, targeting a highly conserved region of the influenza A virus’s Matrix Protein 2 (M2e), showed no viral escape even after a month of repeated exposure. While the study indicates promising results, it is still in the exploratory phase, as findings were based on animal models and have not yet progressed to human trials.

The M2e-mAb triple cocktail therapy proved effective at low doses, significantly reducing disease severity and viral load in both healthy and immunocompromised mice. Notably, when tested against H7N9, a deadly strain of bird flu, one dose of the antibody treatment decreased viral presence in the lungs, leading to improved survival rates. Mice treated within three days of infection showed a 100% survival rate, with lower survival rates for later treatments.

Researchers are now working on humanized versions of these antibodies for future clinical trials, aiming to avoid immune responses that could diminish efficacy. The ultimate goal is to provide a prophylactic treatment, especially for high-risk populations, and a therapeutic option for severely ill patients.

• Why it matters: This research could pave the way for more effective flu treatments, particularly for vulnerable populations, thereby reducing hospitalizations and health risks during flu seasons.
• The latest: The research team is focused on developing humanized antibodies for clinical trials to advance the therapeutic and preventive use of the cocktail.